1. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells
by Yi-Bin Chen, Jennifer Le-Rademacher, Ruta Brazauskas, Deidre M. Kiefer, Mehdi Hamadani, John F. DiPersio, Mark R. Litzow, Michael Craig, Mitchell E. Horwitz, Andrew S. Artz, Brian L. McClune, Hugo F. Fernandez, Hien Kim Duong, Hati Kobusingye, Mandi Proue, Rebecca J. Drexler, Mary M. Horowitz, Bronwen E. Shaw, John P. Miller, Sakura Hosoba, Edmund K. Waller, and Steven M. Devine
BloodAdv
Volume 3(6):
March 26, 2019
© 2019 by The American Society of Hematology

2. Yi-Bin Chen et al. Blood Adv 2019;3:875-883
© 2019 by The American Society of Hematology

3. GVHD outcomes.
GVHD outcomes. (A) Cumulative incidence of grades II-IV acute GVHD. (B) Cumulative incidence of grades III-IV acute GVHD. (C) Cumulative incidence of chronic GVHD. (D) One-year GRFS in RIC and MAC recipients, respectively.
Yi-Bin Chen et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

4. Transplantation outcomes.
Transplantation outcomes. (A) Cumulative incidence of disease relapse. (B) Cumulative incidence of NRM. (C) Progression-free survival. (D) OS in RIC and MAC recipients, respectively.
Yi-Bin Chen et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology